U.S. License Holder:
Genentech, Inc.
Date of License:
September-13-2024
Last Update:
Oct-08-2024
FDA-Approved Indications
OCREVUS ZUNOVO (ocrelizumab; hyaluronidase-ocsq) is a CD20-directed cytolytic antibody indicated for the treatment of:
Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults;
Primary progressive MS, in adults.